Overview

A Study of Pemetrexed and Cyclophosphamide Given Every 21 Days in Advanced Breast Cancer Patients

Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
This is the phase 2 portion of a phase 1/2 trial, testing the use of pemetrexed and cyclophosphamide in combination for the treatment of advanced breast cancer. A single arm Phase 1 dose finding (establish maximum tolerated dose) study precedes the randomized phase 2 portion.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Cyclophosphamide
Pemetrexed